Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 17Neoplasms 14Carcinoma 9Neoplasm Metastasis 7Thoracic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Neoplasms by Site 3Lung Diseases 3Bronchial Neoplasms 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Noonan Syndrome 2Neoplasms, Nerve Tissue 2Neoplasms by Histologic Type 2Meningeal Carcinomatosis 2Head and Neck Neoplasms 2Carcinoma, Bronchogenic 2Breast Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1T790M Positive NSCLC Patients 1Stomach Neoplasms 1

Interventions

Dexamethasone 4pomalidomide 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1gallium 68 PSMA-11 1copanlisib 1carfilzomib 1belinostat 1belantamab mafodotin 1Zoledronic Acid 1Topotecan 1Tablets 1Sitagliptin Phosphate 1Pluvicto 1Paclitaxel 1Lenalidomide 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Renal Insufficiency × osimertinib × Clear all
NCT02923947 2023-11-27

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

AstraZeneca

Phase 1 Completed
16 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡